Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo
PeerJ · 2025
DOI: 10.7717/peerj.19313 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Qingqing Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China. Hauptthemen laut MEDLINE: Carvedilol, Diarylquinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningbo Medical & Health Leading Academic Discipline Project, Ningbo Medical & Health Brand Discipline Project, APC: Traditional Chinese Medicine Pharmaceutical Center Construction Project.
Abstract (Originalsprache)
Bedaquiline has recently been approved for the treatment of multidrug-resistant tuberculosis. Carvedilol is a cardiovascular medication extensively used in the treatment of heart failure and hypertension. In this study, Sprague-Dawley rats, rat liver microsomes (RLM), human liver microsomes (HLM), and recombinant human CYP3A4 were used to explore the effect of carvedilol on the metabolism of bedaquiline. Ultra-performance liquid chromatography-tandem mass spectrometry was used to facilitate the quantification of the analyte concentrations. In vitro, carvedilol did not exhibit time-dependent inhibition of bedaquiline, which aligns with the half-maximal inhibitory concentration (IC 50 ) shift results. The IC 50 values of carvedilol were 15.35 ± 0.43 µM in RLM, 7.55 ± 0.74 µM in HLM, and 0.79 ± 0.05 µM in CYP3A4. Besides, the inhibition type of carvedilol was found to be mixed, un-competitive, and mixed in RLM, HLM, and CYP3A4, respectively. In vivo , the co-administration of carvedilol with bedaquiline resulted in a significant increase in the area under the plasma concentration-time curve (AUC) (0 − t ) , AUC (0 − ∞), and C max of bedaquiline while decreasing its CL z/F . Lay summary : Carvedilol could inhibit the metabolism of bedaquiline in vitro and in vivo , with different mechanisms in different enzymatic reaction systems. Hence, caution should be exercised when combining bedaquiline with carvedilol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Förderung
- Ningbo Medical & Health Leading Academic Discipline Project
- Ningbo Medical & Health Brand Discipline Project
- APC: Traditional Chinese Medicine Pharmaceutical Center Construction Project
Zitieren
APA
Li, Q., Li, W., Chen, J., Lin, H., & Zhou, C. (2025). Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo. PeerJ. https://doi.org/10.7717/peerj.19313
Vancouver
Li Q, Li W, Chen J, Lin H, Zhou C. Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo. PeerJ. 2025. doi:10.7717/peerj.19313
BibTeX
@article{Li2025,
author = {Li, Qingqing and Li, Wanshu and Chen, Jie and Lin, Hangjuan and Zhou, Cixia},
title = {Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.19313}
}
EUVIMED